Joseph M Osborne

US Patent:

40844340, Apr 18, 1978

Filed:

Mar 29, 1977

Appl. No.:

5/782325

Inventors:

Lewis Charles Goodrich - Wilmington DE
Theron Robert Holt - Newark DE
Joseph Cyril Osborne - Wilmington DE
Donald Kirk Pusey - West Grove PA
James William Roxlo - Rockaway NJ

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

D01H 1332

US Classification:

73160

Abstract:

In an apparatus for continuous draw-off of yarn from a package at a measured rate and under regulated tension, the yarn can either be passed to a waste receptacle for a predetermined length of time or can be metered to a scale for subsequent determination of yarn weight per unit length (denier). Diversion of the running yarn from one path to the other is achieved without affecting yarn draw-off rates and tensions.

US Patent:

20220323618, Oct 13, 2022

Filed:

Jan 19, 2022

Appl. No.:

17/579470

Inventors:

- Ithaca NY, US
Joseph Osborne - New York NY, US
Stanley Goldsmith - Floral Park NY, US
Shankar Vallabhajosula - Larchmont NY, US

International Classification:

A61K 51/10
A61K 51/04

Abstract:

A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

US Patent:

20200282085, Sep 10, 2020

Filed:

Oct 15, 2019

Appl. No.:

16/653655

Inventors:

- ITHACA NY, US
Joseph Osborne - New York NY, US
Stanley Goldsmith - Floral Park NY, US
Shankar Vallabhajosula - Larchmont NY, US

International Classification:

A61K 51/10
A61K 51/04

Abstract:

A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

US Patent:

20180133350, May 17, 2018

Filed:

May 19, 2016

Appl. No.:

15/576119

Inventors:

- New York NY, US
Sarah M. Cheal - New York NY, US
Steven M. Larson - New York NY, US
Joseph Reginald Osborne - New York NY, US
Edward Komin Fung - New York NY, US
David Ulmert - New York NY, US

International Classification:

A61K 51/10
G16H 50/50

Abstract:

The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.